API CAS 865759-25-7 Trelagliptin Pharmaceutical Intermediate Trelagliptin Succinate Powder Trelagliptin

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Model NO.: Dsung-Trelagliptin
• Product Name: Trelagliptin
• Name: Trelagliptin Powder
• Appearance: White Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Antidiabetic
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 865759-25-7
• Mf: C18h20fn5o2
• MW: 357.3821032
• Boiling Point: 519.0+-60.0 C(Predicted)
• Density: 1.38+-0.1 g/cm3(Predicted)
• Refractive Index: 1.646
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 500kg/Month

Product Description

API CAS 865759-25-7 Trelagliptin Pharmaceutical Intermediate Trelagliptin Succinate Powder Trelagliptin

 

Product Description

Product Details

Product Name	Trelagliptin
CAS No.	865759-25-7
MF	C18H20FN5O2
MW	357.3821032
Appearance and shape	White Powder

Trelagliptin is the world's first oral hypoglycemic agent once a week. As a DPP-4 inhibitor, troxagliptin is used to inhibit the decomposition of incretin by the enzyme DPP-4 for continuous Promote the secretion of insulin and continuously inhibit the secretion of glucagon to achieve the goal of lowering blood sugar.

Application & Function

Function
Trelagliptin is a weekly dipeptidyl peptidase IV (DPP-4) inhibitor that controls blood glucose levels by selectively and persistently inhibiting DPP-4. Dpp-4 is an enzyme that induces the inactivation of incretin (glucagon-glucagon-like peptides-1 (GLP-1) and glucose-dependent incretin (GIP), which play an important role in blood glucose regulation. Inhibition of DPP-4 can increase the secretion of  dependent on blood glucose level, thus controlling blood glucose level.
Application
Trelagliptin succinate is a dipeptidyl peptidase -IV,DPP- IV) inhibitor developed by Takeda(Takeda Pharmaceutical Co., LTD.) in Japan. It can selectively and persistently inhibit DPP- IV and control blood glucose level. Clinical trials of Chemicalbook show that the drug has a good safety and efficacy, and can effectively control blood glucose levels and improve medication compliance in patients when administered once a week. In May 2015, the drug was approved by PMDA in Japan for the treatment of diabetes.

Specification